Immunology CANCER IMMUNOLOGY

Similar documents
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16

Interaction between the immune system and tumor

Tumor Immunology. Tumor (latin) = swelling

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant

CANCER IMMUNOPATHOLOGY. Eryati Darwin Faculty of Medicine Andalas University

Immune surveillance hypothesis (Macfarlane Burnet, 1950s)

Bihong Zhao, M.D, Ph.D Department of Pathology

Tumor immunology. Tried to make things a simple as they can get,,, hope that u enjoy it! ال تخافوا بس أربع صفحات وشوي

TUMOR M ARKERS MARKERS

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)

Biochemistry of Cancer and Tumor Markers

Basis and Clinical Applications of Interferon

Lecture 4. T lymphocytes

Third line of Defense

BIT 120. Copy of Cancer/HIV Lecture

Prof. Ibtesam Kamel Afifi Professor of Medical Microbiology & Immunology

The Adaptive Immune Responses

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.

Third line of Defense. Topic 8 Specific Immunity (adaptive) (18) 3 rd Line = Prophylaxis via Immunization!

Spontaneous. Tumour induction. Immunosuppression

Chapter 17B: Adaptive Immunity Part II

Title: NATURAL KILLER CELL FUNCTIONS AND SURFACE RECEPTORS

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

C. Incorrect! MHC class I molecules are not involved in the process of bridging in ADCC.

CELL BIOLOGY - CLUTCH CH THE IMMUNE SYSTEM.

Immune system and cancer. Dr. Zafar A Shah Prof. & Head Department of Immunology and Molecular Medicine SKIMS

Anti-infectious Immunity

Adaptive Immune Response Day 2. The Adaptive Immune Response

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust

Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School

A. Incorrect! It s not correct. Synergism of cytokines refers to two or more cytokines acting together.

Rationale for Patient- Specific Vaccine Therapy for Non-Hodgkin Lymphoma

Immunity to Viruses. Patricia Fitzgerald-Bocarsly September 25, 2008

T cell-mediated immunity

Dr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)

Adaptive Immunity: Specific Defenses of the Host

Section D: The Molecular Biology of Cancer

3. A small percentage of tumors, mainly melanomas and some lymphomas, spontaneously regress, presumably due to an immunologic response.

Topics. Humoral Immune Response Part II Accessory cells Fc Receptors Opsonization and killing mechanisms of phagocytes NK, mast, eosynophils

AGAINST VIRAL INFECTIONS. Identify the types of immunity involve in the mechanisms of protection against viral infections.

ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY

Concepts of cancer immunotherapy

Chapter 23 Immunity Exam Study Questions

Cellular Immune response. Jianzhong Chen, Ph.D Institute of immunology, ZJU

3. A small percentage of tumors, mainly melanomas and some lymphomas, spontaneously regress, presumably due to an immunologic response.

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells

Chapter 35 Active Reading Guide The Immune System

Cell Mediated Immunity CELL MEDIATED IMMUNITY. Basic Elements of Cell Mediated Immunity (CMI) Antibody-dependent cell-mediated cytotoxicity (ADCC)

Biological Therapies for Cancer: Questions and Answers

Immunology Lecture 4. Clinical Relevance of the Immune System

Adaptive immune responses: T cell-mediated immunity

Tumor Microenvironment and Immune Suppression

I. Defense Mechanisms Chapter 15

Adaptive Immunity. Jeffrey K. Actor, Ph.D. MSB 2.214,

Immunology - Lecture 2 Adaptive Immune System 1

Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.

Significance of the MHC

Defense mechanism against pathogens

Adaptive (acquired) immunity. Professor Peter Delves University College London

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University

The Innate Immune Response

The Major Histocompatibility Complex (MHC)

CHAPTER-VII IMMUNOLOGY R.KAVITHA, M.PHARM, LECTURER, DEPARTMENT OF PHARMACEUTICS, SRM COLLEGE OF PHARMACY, SRM UNIVERSITY, KATTANKULATHUR.

Adaptive Immunity: Humoral Immune Responses

Principles of Adaptive Immunity

Physiology Unit 3. ADAPTIVE IMMUNITY The Specific Immune Response

Index. Note: Page numbers of article titles are in boldface type.

RAISON D ETRE OF THE IMMUNE SYSTEM:

Genetics and Cancer Ch 20

Genome of Hepatitis B Virus. VIRAL ONCOGENE Dr. Yahwardiah Siregar, PhD Dr. Sry Suryani Widjaja, Mkes Biochemistry Department

Immunity. Acquired immunity differs from innate immunity in specificity & memory from 1 st exposure

Host Defense Mechanisms Adaptive or Acquired Immunity

The Immune System is the Third Line of Defense Against Infection. Components of Human Immune System

Immunological Aspects of Parasitic Diseases in Immunocompromised Individuals. Taniawati Supali. Department of Parasitology

Neoplasia 2018 lecture 11. Dr H Awad FRCPath

MCB 4211 Basic Immunology 2nd Exam; 10/26/17 Peoplesoft #:

Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD

Immunotherapy on the Horizon: Adoptive Cell Therapy

T cell Receptor. Chapter 9. Comparison of TCR αβ T cells

5/1/13. The proportion of thymus that produces T cells decreases with age. The cellular organization of the thymus

3. Lymphocyte proliferation (fig. 15.4): Clones of responder cells and memory cells are derived from B cells and T cells.

The Adaptive Immune Response. T-cells

A Multicistronic DNA Vaccine Induces Significant Protection against Tuberculosis in Mice and Offers Flexibility in the Expressed Antigen Repertoire.

The Immune System. These are classified as the Innate and Adaptive Immune Responses. Innate Immunity

Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach

Transplantation. Immunology Unit College of Medicine King Saud University

LYMPHOCYTES & IMMUNOGLOBULINS. Dr Mere Kende, Lecturer SMHS

Overview of the immune system

2014 Pearson Education, Inc. Exposure to pathogens naturally activates the immune system. Takes days to be effective Pearson Education, Inc.

CHAPTER 18: Immune System

They determine if there will be an immune response. Determine functions associated with immune response, but not specific to Ag.

Blood and Immune system Acquired Immunity

General Biology. A summary of innate and acquired immunity. 11. The Immune System. Repetition. The Lymphatic System. Course No: BNG2003 Credits: 3.

Chapter 10 (pages ): Differentiation and Functions of CD4+ Effector T Cells Prepared by Kristen Dazy, MD, Scripps Clinic Medical Group

T Cell Effector Mechanisms I: B cell Help & DTH

How T cells recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do? Monoclonal antibody approach

A second type of TCR TCR: An αβ heterodimer

Introduction to Cancer Biology

Transcription:

Immunology د. عائدة الدرزي Lec. 6 CANCER IMMUNOLOGY Oncogenesis (passes through two stages): 1- Reversible change Normal transformed cells 2- Irreversible change Transformed oncogenic cells Factors causing oncogenesis: 1 - Hereditary predisposition 2- Environmental factors: They cause mutations & have been shown to induce transformation, they include: a- Physical agents: Ultraviolet light, ionizing radiation...etc b- Chemical agents: Aromatic amines, Afla toxins, alcohol..etc. c- Viral factors: A number of DNA & RNA have been shown to induce malignant transformation. e.g. herpes virus II ca. Cervix Cytomegalo virus (CMV) nasopharyngeal ca. 1

3- Involvement of normal regulatory genes (cancer associated genes): Cancer associated genes can be divided into 3 categories that reflect their different activities: a- The growth promoting / proto-oncogenes : These genes encode proteins that induce cellular proliferation. Some of these proteins function as growth factors, growth factor receptors, signal transducers, & transcription factors. Over activities of these genes (due to mutation, genetic rearrangement, chromosomal translocations) results in up regulated proliferations. b- The growth inhibiting / cancer suppressor genes : These genes encode proteins that inhibit excessive cell proliferations. Inactivation of these genes results in un- regulated proliferations. Ex. P 53 : > 50% of breast & ovarian cancers have been shown to be associated with mutation in P53. c- Genes that regulate apoptosis : They encode proteins that block or induce apoptosis. Ex. bcl 2 (anti-apoptosis gene) 2

Theory of oncogenesis by oncogenes: Oncogenes were shown to cause neoplastic transformation of cell in vitro, & were therefore regarded as the gene that causes cancer. They occur in all eukaryotic cells including man. More than 30 oncogens have been identified & around 28 have been mapped. The protein of oncogen have been found to be similar to known substances that are known to be involved in the control of the cell division; growth factor; plasma membrane receptors; modulation of transduction of oncogenes signals through plasma membrane. These new discoveries changed the new concept of oncogen, i.e. they are considered to play a vital role in the normal control of mitosis, so they are regarded as mitogenes rather than oncogenes. Most prominent changes associated with transformed cells: 1- Altered morphology 2- Altered pattern of growth (physiological changes) 3- Biochemical changes include: - metabolic rate - Changes in the composition - Changes in the proteins of cell membrane, these changes include: a. Loss of normal cell surface Ag b. Gain of neoantigens & other membrane changes Tumor immunology involves: 1- Study of antigens on tumor cells 2- Immune response to these antigens 3

Tumor Antigens: 1- Tumor specific transplantation Ag (TSTA) 2- Oncofetal tumor antigens (Embryonic Ag) 3- Tumor associated transplantation Ag (TATA) 4- Tumor associated viral Ag 4

Tumor Antigens: 1- TSTA, these are: - Specific Ags - Unique to tumor cells, & do not occur on normal cells - result from mutation,& tumor cells generate altered cellular peptides e.g. PSA (prostate specific antigen) 2- Oncofetal tumor antigens: a- Alpha fetoprotein (AFP) - These are associated with: - Primary liver cancer - Testicular & ovarian cancer - Gastric & pancreatic cancer - Liver cirrhosis & hepatitis b- Carcinoembryonic Ag (CEA)- These are associated with: - Colorectal cancer - Pancreatic cancer - Liver cirrhosis, chronic lung disease 3- TATAs e.g. myeloma pr., CALLA 4- Tumor associated viral Ags Immune response to tumor: I- Non-specific immunity: a- Macrophages: not MHC restricted, so it kills tumor cells inspecifically - Activated macrophages express Fc-receptors that bind Ab on tumor cells kill the target cells by ADCC - Anti-tumor activity of macrophages is mediated by: Hydrolytic enzymes, cytokines, INF-ү, TNF-α, oxidative products (H 2 O 2 ), nitric oxide directly kill tumor cells 5

Macrophage act against tumor in two ways: 1- Antibody binds to tumor cell Ag & FcyR on macrophage 2- Direct contact of new surface determinants on tumor cell & macrophage receptors b- Natural killer cells: not MHC restricted - NK cells express Fc-receptors that bind Ab on tumor cells kill the target cell by ADCC through releasing of Perforine, granzymes, & proteases -Direct contact INF-Ү - Activates non active NK - Hyper activates the already active NK - Makes NK resistant to PGE 2 6

Immune response to tumor: II- Specific immunity by: a- Cell mediated immunity: - CD8 + cell (Tc) direct hit & run phenomenon perforine & granzymes granules - CD4 + cell (TDTH) indirectly by cytokines (MIF, MAF, MCF, IL 2, TNFβ) b- Humoral immune response - Complement fixation - Opsonization - ADCC 7

Modes of escape from host defence mechanisms: 1- Tumor is non-immunogenic 2- Tumor modulates it's surface Ag avoid immune destruction 3- Loss of class I MHC molecules Tu. cannot be destroyed by MHCrestricted cytotoxic T-cell 4- Immune enhancement (blocking factors): Tumor-growth-enhancing Abs protect tumor cells & prevent their interaction with protective immune factors 5- Ag shedding: continuous shedding of Ag local & systemic tolerance 6- Lack of co-stimulatory signal (B 7 ) no immune response 7- Tumor secrets immune-suppressive molecules (immune-kinetics) e.g. PGE 2 immune response is down regulated 8- Ag masking: tumor products mask the antigenic determinant area hidden 8

Cancer immunotherapy: a- Immunotoxines: Tumor specific monoclonal Abs conjugated to tumoricidal substances. e.g. cytotoxic drugs, diphtheria toxin... etc. (Magic bullet) b- Macrophage activating compounds: - Bacille Calmette-Guerin (BCG) - Cytokine therapy: 1- INF-ү.β.α- class I MHC on T-cell 2- INF-y class II MHC especially on macrophage Inhibits cell division & proliferation Activity of NK, Tc 3- TNF-α & β direct anti-tumor activity 4- IL 2 T & NK activation c- Cytokine genes (genetic engineering) 1- GM-CSF gene 2- IL 12 gene 9